Anemia, Diabetes, and Chronic Kidney Disease

Mehdi, Uzma F.; Toto, Robert D.

doi:10.2337/dc08-0779

Cited by 207 publications

(215 citation statements)

References 66 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…Other causes for anaemia in CKD include the presence of uremic inhibitors (e.g., parathyroid hormone, inflammatory cytokines), reduced half-life of circulating blood cells and deficiencies of folate or vitamin B12. 10 As CKD patients commonly presents with anorexia, nausea and vomiting, less dietary intake of nutrients needed for erythropoiesis might also be a factor for anaemia in this group of patients. Moreover, CKD patients are on protein restricted diet which might also have some role for occurrence of anaemia in this series of patients.…”

Section: Introductionmentioning

confidence: 99%

Iron status in chronic kidney disease patients

Deori

Bhuyan²

2016

Int J Res Med Sci

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Iron status in chronic kidney disease patients

Deori

Bhuyan²

2016

Int J Res Med Sci

View full text Add to dashboard Cite

“…In addition, thiazolidinediones, which include pioglitazone (Actos) and rosiglitazone (Avandia), can also cause mild anaemia by slightly decreasing haemoglobin levels and haematocrit, a measurement of the proportion of blood that is made up of RBCs. According to Mehdi and Toto, 19 Marathias et al 20 and Mohanram et al, 21 angiotensinconverting enzyme (ACE) inhibitors and angiotensin receptor antagonists may cause a reversible decrease in haemoglobin concentration in patients with diabetes. The mechanisms by which ACE inhibitors and angiotensin receptor blockers lower haemoglobin include a direct blockade of the pro-erythropoietic effects of angiotensin II on red cell precursors, degradation of physiological inhibitors of haematopoiesis and suppression of insulin-like growth factor -1 (IGF-I).…”

Section: Markers Of Anaemiamentioning

confidence: 99%

Diabetes mellitus: A review of some of the prognostic markers of response to treatment and management

Agu

2018

JMH

View full text Add to dashboard Cite

Background: The WHO defined ‘diabetes mellitus’ (DM) as a metabolic disorder characterised by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from the defect in insulin secretion, or inaction, or both. When not identified early and controlled, acute and chronic life-threatening consequences may result. Identifying DM early for treatment and management, as well as clinically monitoring recovery and improvement during treatment, involves the assessments of biomarkers. The types, choice, sensitivity and descriptive information trends of these biomarkers are very important. Aim: Some prognostic biomarkers and parameters that this review identified include glycated haemoglobin, white blood cells, mean neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, total leukocytes and neutrophils, plasma low-density lipoprotein, high-density lipoprotein and very low-density lipoprotein, platelet, fibrinogen, D-dimer and C-reactive proteins. Results: These parameters display increases in DM, while red blood cell, haemoglobin concentration, activated partial thromboplastin time, prothrombin time and partial thromboplastin time are decreased. Conclusion: With sound knowledge of the variations of these markers and parameters, observed reversal during treatment and management of DM and its complications can be better monitored, and guided decisions can be made.

show abstract

“…Therefore, imature erythrocytes become fragile and lysis (neocytolisis). From microscopic observation, erythrocytes have normocytic and normochromic features that is different from erythrocyte features of iron deficiency anemia (Hayat et al, 2008;Mehdi & Toto, 2009). …”

Section: Introductionmentioning

confidence: 99%